☰

Parvez F. Vora, Ph.D. - Publications

Affiliations: 
2012 Pharmacy University of Manitoba, Winnipeg, Manitoba, Canada 
Area:
Neuroscience Biology, Cell Biology, Pharmacy
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

50 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Kieliszek AM, Mobilio D, Upreti D, Bloemberg D, Escudero L, Kwiecien JM, Alizada Z, Zhai K, Ang P, Chafe SC, Vora P, Venugopal C, Singh SK. Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37787999 DOI: 10.1158/1078-0432.CCR-23-1735  0.379
2020 Upreti D, Bakhshinyan D, Bloemberg D, Vora P, Venugopal C, Singh SK. Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. Frontiers in Immunology. 11: 599253. PMID 33281826 DOI: 10.3389/fimmu.2020.599253  0.309
2020 Vora P, Venugopal C, Salim SK, Tatari N, Bakhshinyan D, Singh M, Seyfrid M, Upreti D, Rentas S, Wong N, Williams R, Qazi MA, Chokshi C, Ding A, Subapanditha M, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. PMID 32464096 DOI: 10.1016/J.Stem.2020.04.008  0.4
2019 Vora P, Seyfrid M, Venugopal C, Qazi MA, Salim S, Isserlin R, Subapanditha M, O'Farrell E, Mahendram S, Singh M, Bakhshinyan D, Chokshi C, McFarlane N, Dvorkin-Gheva A, Brown KR, et al. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. Journal of Neuro-Oncology. PMID 31115870 DOI: 10.1007/S11060-019-03192-1  0.475
2019 Hu AX, Adams JJ, Vora P, Qazi M, Singh SK, Moffat J, Sidhu SS. EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. Methods in Molecular Biology (Clifton, N.J.). 1869: 155-168. PMID 30324522 DOI: 10.1007/978-1-4939-8805-1_14  0.401
2019 Vora P, Venugopal C, Chokshi C, Qazi M, Tatari N, Brown K, Yelle N, Adams J, Tieu D, Seyfrid M, Singh M, Savage N, Subapanditha M, Bakhshinyan D, Kuhlmann L, et al. Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence Cancer Research. 79: 570-570. DOI: 10.1158/1538-7445.Am2019-570  0.416
2018 Bakhshinyan D, Venugopal C, Adile AA, Garg N, Manoranjan B, Hallett R, Wang X, Mahendram S, Vora P, Vijayakumar T, Subapanditha M, Singh M, Kameda-Smith MM, Qazi M, McFarlane N, et al. BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. PMID 30348991 DOI: 10.1038/S41388-018-0549-9  0.418
2018 Singh M, Venugopal C, Tokar T, McFarlane N, Subapanditha MK, Qazi M, Bakhshinyan D, Vora P, Murty N, Jurisica I, Singh SK. Therapeutic targeting of the pre-metastatic stage in human brain metastasis. Cancer Research. PMID 29986997 DOI: 10.1158/0008-5472.Can-18-1022  0.436
2018 Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu AX, Gorelik M, Subapanditha MK, Savage N, Yang J, Chokshi C, London M, Gont A, Bobrowski D, Grinshtein N, et al. Co-targeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma. Cancer Research. PMID 29945963 DOI: 10.1158/0008-5472.Can-18-0267  0.4
2018 Singh M, Venugopal C, Tokar T, McFarlane N, Subhapanditha M, Bakhshinyan D, Qazi M, Vora P, Savage N, Murty NK, Jurisica I, Singh SK. Abstract 44: Characterization and targeting of a temporal micro-metastatic signature in human brain metastases Tumor Biology. DOI: 10.1158/1538-7445.Am2018-44  0.356
2018 Chokshi C, Tieu D, Brown K, Venugopal C, Vora P, Chan K, Tong A, Qazi M, Singh M, Savage N, Habsid A, Moffat J, Singh S. Abstract 390: Genome-wide CRISPR screens in brain tumor initiating cells (BTICs) identify potent sensitizers and resistors of conventional chemoradiotherapy Cancer Research. 78: 390-390. DOI: 10.1158/1538-7445.Am2018-390  0.382
2018 Vora P, Adams J, Singh M, Venugopal C, Tatari N, Chokshi C, Qazi M, Salim S, Mahendram S, Bakhshinyan D, London M, Savage N, Subapanditha M, McFarlane N, Pan J, et al. Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies Cancer Research. 78: 1763-1763. DOI: 10.1158/1538-7445.Am2018-1763  0.425
2017 Singh M, Venugopal C, Tokar T, Brown KR, McFarlane N, Bakhshinyan D, Vijayakumar T, Manoranjan B, Mahendram S, Vora P, Qazi M, Dhillon M, Tong A, Durrer K, Murty N, et al. RNAi screen identifies essential regulators of human brain metastasis-initiating cells. Acta Neuropathologica. PMID 28766011 DOI: 10.1007/S00401-017-1757-Z  0.433
2017 Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, Singh SK. Intratumoral Heterogeneity: Pathways to Treatment Resistance and Relapse in Human Glioblastoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28407030 DOI: 10.1093/Annonc/Mdx169  0.402
2017 Vora P, Chokshi C, Qazi M, Singh M, Venugopal C, Mahendram S, Adams J, Bakhshinyan D, London M, Singh J, Subapanditha M, McFarlane N, Pan J, Bramson J, Sidhu S, et al. Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma Cancer Research. 77: 3758-3758. DOI: 10.1158/1538-7445.Am2017-3758  0.395
2017 Qazi M, Vora P, Chokshi C, Venugopal C, London M, Hu A, Subapandtiha M, Singh M, Adams J, Moffat J, Sidhu S, Singh SK. Abstract 3639: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma Cancer Research. 77: 3639-3639. DOI: 10.1158/1538-7445.Am2017-3639  0.415
2017 Chokshi C, Tieu D, Vora P, Venugopal C, Chan K, Tong A, Brown K, Singh M, Moffat J, Singh S. Stem-42. Genome-Wide Crispr Screens In Brain Tumor Initiating Cells (Btics) Identify Potent Sensitizers Of Conventional Chemoradiotherapy. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.956  0.374
2017 Seyfrid M, Chokshi C, Kuhlmann L, Venugopal C, Vora P, Sinha A, Ignatchenko V, Macklin A, Kislinger T, Singh S. Stem-17. Characterization Of The Cell Surface Proteome In Recurrent Glioblastoma Initiating Cells Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.933  0.342
2017 Qazi M, Vora P, Venugopal C, Gorelik M, Singh M, Hu A, Subapanditha M, Chokshi C, Savage N, Yelle N, Adams J, Moffat J, Sidhu S, Singh S. IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC
EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA Neuro-Oncology. 19: vi113-vi113. DOI: 10.1093/Neuonc/Nox168.462  0.418
2017 Manoranjan B, Venugopal C, Mahendram S, Subapanditha M, Savage N, Qazi M, Vora P, Moffat J, Doble B, Singh S. CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS Neuro-Oncology. 19: vi54-vi54. DOI: 10.1093/Neuonc/Nox168.216  0.391
2017 Singh M, Venugopal C, Tokar T, McFarlane N, Bakhshinyan D, Qazi M, Vora P, Murty N, Jurisica I, Singh S. CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES Neuro-Oncology. 19: vi49-vi49. DOI: 10.1093/Neuonc/Nox168.193  0.364
2017 Singh M, Venugopal C, Vora P, Adams J, Pan J, Chokshi C, Murty N, Sidhu S, Moffat J, Singh S. CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.182  0.37
2016 Tripathi A, Parikh ZS, Vora P, Frost EE, Pillai PP. pERK1/2 Peripheral Recruitment and Filopodia Protrusion Augment Oligodendrocyte Progenitor Cell Migration: Combined Effects of PDGF-A and Fibronectin. Cellular and Molecular Neurobiology. PMID 26993510 DOI: 10.1007/S10571-016-0359-Y  0.355
2016 Vora P, Qazi M, Chokshi C, Venugopal C, London M, Hu A, McFarlane N, Subapanditha M, Singh M, Mahendram S, Adams J, Moffat J, Sidhu S, Singh S. Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B092  0.455
2016 Vora P, Chokshi C, Qazi M, Venugopal C, Mahendram S, Singh M, Adams J, Bakhshinyan D, London M, Subapanditha M, McFarlane N, Pan J, Bramson J, Moffat J, Sidhu S, et al. Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B079  0.388
2016 Vora P, Qazi M, Venugopal C, Subapanditha M, Mahendram S, Chokshi C, Singh M, Bakhshinyan D, McFarlane N, Singh S. Abstract 2512: Bmi1 identifies treatment-refractory stem cells in human glioblastoma Cancer Research. 76: 2512-2512. DOI: 10.1158/1538-7445.Am2016-2512  0.461
2016 Vora P, Venugopal C, Mahendram S, Chokshi C, Qazi M, Subapanditha M, Singh M, Bakhshinyan D, Bezverbnaya K, Adams J, McFarlane N, Sidhu S, Moffat J, Bramson J, Singh S. Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors Cancer Research. 76: 2300-2300. DOI: 10.1158/1538-7445.Am2016-2300  0.381
2016 Vora P, Venugopal C, Adams J, Pan J, Chokshi C, Qazi M, Subapanditha M, Singh M, Bakhshinyan D, Bezverbnaya K, McFarlane N, Bramson J, Sidhu S, Moffat J, Singh S. Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells Cancer Research. 76: 1481-1481. DOI: 10.1158/1538-7445.Am2016-1481  0.401
2016 Singh M, Venugopal C, Tokar T, Brown K, McFarlane N, Bakhshinyan D, Vora P, Qazi M, Mahendram S, Vijaykumar T, Manoranjan B, Tong A, Durrer K, Murty N, Hallet R, et al. TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS Neuro-Oncology. 18: vi211-vi212. DOI: 10.1093/Neuonc/Now212.893  0.385
2016 Qazi M, Vora P, Venugopal C, Bakhshinyan D, Nixon A, Brown K, Subapanditha M, Chokshi C, Murty N, Moffat J, Singh S. TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.872  0.336
2016 Vora P, Chokshi C, Qazi M, Venugopal C, Mahendram S, Singh M, Adams J, London M, Bakhshinyan D, Subapanditha M, McFarlane N, Pan J, Bramson J, Moffat J, Sidhu S, et al. IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.409  0.328
2016 Vora P, Venugopal C, Choksi C, Qazi M, Adams J, London M, Subapanditha M, Singh M, Bakshinyan D, Sidhu S, Moffat J, Singh S. PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.367  0.352
2016 Vora P, Qazi M, Venugopal C, Subapanditha M, Mahendram S, Chokshi C, Singh M, Bakhshinyan D, McFarlane N, Singh S. PS2 - 171 Bmi1 Identifies Treatment-Refractory Stem Cells in Human Glioblastoma Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.366  0.35
2016 Bakhshinyan D, Vijayakumar T, Manoranjan B, McFarlane N, Venugopal C, Singh M, Qazi M, Vora P, Singh S. PS1 - 169 Discovering the Treatment Refractory BTIC Population in Group 3 Medulloblastoma through Therapy Adapted Patient-Derived Human Mouse Xenograft (PDX) Model Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.357  0.307
2016 Singh M, Venugopal C, Tokar T, Brown KR, McFarlane N, Bakhshinyan D, Vijayakumar T, Manoranjan B, Mahendram S, Vora P, Qazi M, Dhillon M, Tong A, Durrer K, Murty N, et al. OS2 - 166 A Novel Model of Human Lung-to-Brain Metastasis and its Application to the Identification of Essential Metastatic Regulatory Genes Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 43: S2-S2. DOI: 10.1017/Cjn.2016.333  0.43
2016 Qazi MA, Vora P, Venugopal C, Bakhshinyan D, Nixon A, McFarlane N, Subapanditha MK, Murty NK, Hallett RM, Moffat J, Singh SK. Modelling Therapy Resistance for the Identification of Treatment-Refractory Cell Population(s) in Human Glioblastoma Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.330  0.329
2015 Qazi MA, Vora P, Venugopal C, McFarlane N, Subapanditha MK, Murty NK, Hassell JA, Hallett RM, Singh SK. A novel stem cell culture model of recurrent glioblastoma. Journal of Neuro-Oncology. PMID 26498281 DOI: 10.1007/S11060-015-1951-6  0.468
2015 Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, Mahendram S, Bakhshinyan D, Manoranjan B, Vora P, Qazi M, Arpin CC, Page B, Haftchenary S, Rosa DA, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. PMID 26314961 DOI: 10.18632/Oncotarget.4742  0.391
2015 Vora P, Venugopal C, McFarlane N, Singh SK. Culture and Isolation of Brain Tumor Initiating Cells. Current Protocols in Stem Cell Biology. 34: 3.3.1-3.3.13. PMID 26237571 DOI: 10.1002/9780470151808.sc0303s34  0.344
2015 Singh SK, Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi M, McFarlane N, Subapanditha M, Nolte S, Singh M, Bakhshinyan D, Garg N, Vijayakumar T, Lach B, et al. Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26152745 DOI: 10.1158/1078-0432.Ccr-14-3147  0.433
2015 Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi M, McFarlane N, Subapanditha M, Nolte S, Singh M, Bakhshinyan D, Garg N, Boleslaw L, John P, Reddy K, et al. STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS Neuro-Oncology. 17: v213.1-v213. DOI: 10.1093/Neuonc/Nov234.23  0.451
2015 Vora P, Qazi M, Venugopal C, Subapanditha M, Bakhshinyan D, Mahendram S, McFarlane N, Singh S. ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.92  0.449
2014 Qazi M, Mann A, van Ommeren R, Venugopal C, McFarlane N, Vora P, Singh SK. Generation of murine xenograft models of brain tumors from primary human tissue for in vivo analysis of the brain tumor-initiating cell. Methods in Molecular Biology (Clifton, N.J.). 1210: 37-49. PMID 25173159 DOI: 10.1007/978-1-4939-1435-7_4  0.413
2014 Vora P, Venugopal C, Qazi M, Mahendram S, McFarlane N, Singh S. SC-33POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou275.32  0.434
2014 Qazi M, Vora P, Venugopal C, McFarlane N, Hallett R, Singh S. Rm-06In Vitro Clonal Evolution Of Glioblastoma (Gbm) Brain Tumour Initiating Cells (Btic) To Model Tumour Recurrence Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou273.6  0.472
2014 Singh SK, Manoranjan B, Venugopal C, Vora P, McFarlane N, Garg N, Singh M, Mann A, Bakhshinyan D, Mahendran S, Dunn S. Sox2 Identifies The Treatment-Refractory Stem Cell Population In Group 2 Medulloblastoma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.16  0.458
2012 Vora P, Pillai P, Mustapha J, Kowal C, Shaffer S, Bose R, Namaka M, Frost EE. CXCL1 regulation of oligodendrocyte progenitor cell migration is independent of calcium signaling. Experimental Neurology. 236: 259-67. PMID 22554866 DOI: 10.1016/J.Expneurol.2012.04.012  0.651
2012 Zhu W, Frost EE, Begum F, Vora P, Au K, Gong Y, Macneil B, Pillai P, Namaka M. The role of dorsal root ganglia activation and brain-derived neurotrophic factor in multiple sclerosis Journal of Cellular and Molecular Medicine. 16: 1856-1865. PMID 22050733 DOI: 10.1111/J.1582-4934.2011.01481.X  0.632
2011 Vora P, Pillai PP, Zhu W, Mustapha J, Namaka MP, Frost EE. Differential effects of growth factors on oligodendrocyte progenitor migration. European Journal of Cell Biology. 90: 649-56. PMID 21616555 DOI: 10.1016/J.Ejcb.2011.03.006  0.384
2010 Vora P, Mina R, Namaka M, Frost EE. A novel transcriptional regulator of myelin gene expression: Implications for neurodevelopmental disorders Neuroreport. 21: 917-921. PMID 20697302 DOI: 10.1097/Wnr.0B013E32833Da500  0.322
Show low-probability matches.